Literature DB >> 15733882

Low-dose secnidazole in the treatment of bacterial vaginosis.

J T Núñez1, G Gómez.   

Abstract

OBJECTIVE: To determine whether bacterial vaginosis could be cured with a single 1-g oral dose of secnidazole.
MATERIAL AND METHODS: A total of 80 women were recruited at the outpatient gynecologic clinic of Manuel Noriega Hospital, Maracaibo, Venezuela. Diagnosis and patient enrollment were based on the Amsel criteria. The participants were randomized to 2 groups. In group 1 (n=44) participants received a single 1-g oral dose and in group 2 (n=32) participants received a single 2-g oral dose of secnidazole. Clinical cure was defined as the absence of the characteristic symptoms (a bad odor and a grossly abnormal discharge) and at least 2 of the following: vaginal pH less than 4.5, no fish odor on addition of KOH, and no Gardnerella vaginalis or clue cells on wet-mount examination. Cytologic cure was defined as an absence of G. vaginalis on a Papanicolaou (Pap) smear.
RESULTS: Clinical cure was experienced by 95.5% of the women who received the 1-g oral dose and by 97.4% of the women who received the 2-g oral dose of secnidazole. There was no significant difference between the groups in the clinical resolution of bacterial vaginosis. Following treatment, results were negative for G. vaginalis in 94.7% of the women. In group 1, 41 women (93.2%), and in group 2, 31 women (96.9%) had cytologic cure. The Pap smear revealed G. vaginalis in 3 of the women in group 1 and 1 of the women in group 2 (P=0.47). Twenty-seven women (35.5%) reported mild side effects. More women had adverse effects in group 1 (n=16) than in group 2 (n=11) but this difference was not statistically significant.
CONCLUSION: This clinical study showed that a single 1-g oral dose of secnidazole is effective to cure bacterial vaginosis associated with G. vaginalis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15733882     DOI: 10.1016/j.ijgo.2004.11.028

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  5 in total

1.  In Vitro Study of the Susceptibility of Clinical Isolates of Trichomonas vaginalis to Metronidazole and Secnidazole.

Authors:  Arindam P Ghosh; Cheri Aycock; Jane R Schwebke
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

2.  Treatment of bacterial vaginosis: a multicenter, double-blind, double-dummy, randomised phase III study comparing secnidazole and metronidazole.

Authors:  Jean-Marc Bohbot; Eric Vicaut; Didier Fagnen; Michel Brauman
Journal:  Infect Dis Obstet Gynecol       Date:  2010-09-15

3.  Antibacterial treatment of bacterial vaginosis: current and emerging therapies.

Authors:  Jean-Pierre Menard
Journal:  Int J Womens Health       Date:  2011-08-23

4.  Secnidazole for treatment of bacterial vaginosis: a systematic review.

Authors:  Mohamed A Abd El Aziz; Foruzan Sharifipour; Parvin Abedi; Shayesteh Jahanfar; Helen Marie Judge
Journal:  BMC Womens Health       Date:  2019-10-21       Impact factor: 2.809

Review 5.  Bacterial Vaginosis Biofilms: Challenges to Current Therapies and Emerging Solutions.

Authors:  Daniela Machado; Joana Castro; Ana Palmeira-de-Oliveira; José Martinez-de-Oliveira; Nuno Cerca
Journal:  Front Microbiol       Date:  2016-01-20       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.